ASCO 2015 Highlights

Chemohormonal Therapy versus Hormonal Therapy Alone in Men with Metastatic Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

AR-V7 Splice Variant as Prognostic Marker for Resistance to Enzalutamide or Abiraterone in Men with Metastatic Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Nivolumab versus Investigator’s Choice of Chemotherapy in Patients with Advanced Melanoma

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Nivolumab Improves Survival in Ipilimumab-Naïve Patients with Advanced Melanoma

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Two Dosing Schedules of Pembrolizumab for Patients with Advanced Melanoma

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Updated OS Data for the CA184-043 Trial: Immunotherapy with Ipilimumab Does Not Improve Survival in Patients with Metastatic Prostate Cancer

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Afatinib Improves Outcomes in Patients with Head and Neck Cancer

ESMO 2014 - Gastrointestinal and Head & Neck Cancer, ESMO

Conference Correspondent

Association of HPV and p16 Status with Cetuximab plus Radiotherapy in Locally Advanced Head and Neck Cancer

ESMO 2014 - Gastrointestinal and Head & Neck Cancer, ESMO

Conference Correspondent

Pembrolizumab in HPV-Positive Head and Neck Cancer

ESMO 2014 - Gastrointestinal and Head & Neck Cancer, ESMO

Conference Correspondent

Cetuximab, Fluorouracil, and Cisplatin, with/without Docetaxel, in Recurrent or Metastatic Head and Neck Cancer

ESMO 2014 - Gastrointestinal and Head & Neck Cancer, ESMO

Conference Correspondent

Page 214 of 329